Sumitomo Pharma Co.,Ltd. [4506.T]
TOKYO, Apr 08 (Pulse News Wire) – Sumitomo Pharma CO.,LTD. (4506.T) announced today that it has decided to refinance existing loans through a bridge loan facility.
The purpose of this refinancing includes repayment of existing borrowings secured by Sumitomo Chemical Co., Ltd. and transitioning to a new unsecured bridge loan arrangement. The bridge loan facility consists of term loans and committed lines totaling ¥20.00 billion and ¥130.0 billion. It will be used for refinancing existing borrowings and working capital purposes. The borrowing period runs from April 24, 2026 to April 23, 2027, with a lump-sum repayment method.
There will be no collateral or guarantors involved, and the loan will be sourced from Sumitomo Mitsui Banking Corporation and others. In addition, the company plans to issue new shares and sell its own stock, alongside repaying existing syndicated loans. The initial amount of the syndicated loans was ¥140.0 billion and ¥93.00 billion, with outstanding balances of ¥60.00 billion and ¥38.10 billion as of April 8, 2026. These loans were also set up for refinancing existing borrowings and working capital needs, with a borrowing period from March 31, 2025 to March 31, 2028. This refinancing activity is expected to have a minor impact on the company's consolidated performance for the fiscal year ending March 2027.
However, future predictions included in this press release are based on assumptions and judgments made as of the release date and are subject to various risks and uncertainties.
🟢 Confidence: High AI-translated content.